Tenax Therapeutics (NASDAQ:TENX) Share Price Breaks Above Fifty Day Moving Average – Should You Sell?

Posted by Brenda Bartman on Oct 29th, 2026

Tenax Therapeutics, Inc. (NASDAQ:TENX – Get Free Report)’s stock price crossed above its fifty day moving average during trading on Wednesday. The stock has a fifty day moving average of $1.84 and traded as high as $1.89. Tenax Therapeutics shares last traded at $1.88, with a volume of 1,653,196 shares.

Trending Headlines about Tenax Therapeutics

Here are the key news stories impacting Tenax Therapeutics this week:

Neutral Sentiment: Investors who purchased Tenax securities between November 13, 2023, and August 7, 2026, may seek appointment as lead plaintiff. The stated deadline is December 28, 2026. Several firms, including Rosen Law Firm, Faruqi & Faruqi, Bronstein Gewirtz & Grossman, and Portnoy Law, issued investor notices. Rosen Law Firm securities fraud lawsuit notice
Negative Sentiment: The lawsuit, filed in federal court against Tenax and certain officers, seeks damages under federal securities laws. Repeated announcements from multiple law firms increase the visibility of the litigation and add legal, financial, and reputational risk for shareholders. Pomerantz class-action filing
Negative Sentiment: Shareholder allegations include claims that Tenax overstated the effectiveness of its lead candidate TNX-103, as well as its clinical, regulatory, and commercial prospects. Other complaints allege investors were misled about the viability of the company’s levosimendan program. These are allegations, not proven findings, but they directly challenge the company’s core investment thesis. Holzer and Holzer investor alert

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. UBS Group cut shares of Tenax Therapeutics to a “neutral” rating in a research report on Monday, August 31st. Wall Street Zen cut shares of Tenax Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Chardan Capital downgraded shares of Tenax Therapeutics from a “buy” rating to a “neutral” rating and set a $5.00 price target on the stock. in a research note on Tuesday, August 11th. Canaccord Genuity Group set a $4.00 price target on shares of Tenax Therapeutics and gave the company a “buy” rating in a research note on Tuesday, August 11th. Finally, Roth Capital set a $5.00 price objective on shares of Tenax Therapeutics in a report on Monday, August 10th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $14.00.

Get Our Latest Research Report on TENX

Tenax Therapeutics Stock Up 9.3%

The firm has a 50-day moving average price of $1.84 and a 200 day moving average price of $10.23. The firm has a market capitalization of $70.36 million, a PE ratio of -1.27 and a beta of 0.92.

Tenax Therapeutics (NASDAQ:TENX – Get Free Report) last issued its quarterly earnings data on Friday, July 31st. The specialty pharmaceutical company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.03. Equities research analysts expect that Tenax Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Insider Buying and Selling

In other news, major shareholder Adar1 Capital Management, Llc bought 900,000 shares of the company’s stock in a transaction on Thursday, September 3rd. The stock was bought at an average cost of $1.78 per share, with a total value of $1,602,000.00. Following the transaction, the insider directly owned 6,524,151 shares in the company, valued at $11,612,988.78. The trade was a 16.00% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last three months, insiders bought 3,682,899 shares of company stock worth $6,388,279. Company insiders own 10.81% of the company’s stock.

Institutional Trading of Tenax Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. State of Alaska Department of Revenue purchased a new position in shares of Tenax Therapeutics in the third quarter valued at approximately $94,000. Bank of America Corp DE grew its holdings in shares of Tenax Therapeutics by 391.2% in the first quarter. Bank of America Corp DE now owns 18,569 shares of the specialty pharmaceutical company’s stock valued at $297,000 after purchasing an additional 14,789 shares in the last quarter. Squarepoint Ops LLC purchased a new stake in Tenax Therapeutics during the 2nd quarter worth approximately $485,000. The Manufacturers Life Insurance Company purchased a new stake in Tenax Therapeutics during the 1st quarter worth approximately $501,000. Finally, Dimensional Fund Advisors LP purchased a new stake in Tenax Therapeutics during the 1st quarter worth approximately $1,001,000. 1.67% of the stock is currently owned by hedge funds and other institutional investors.

Tenax Therapeutics Company Profile

(Get Free Report)

Tenax Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular and pulmonary diseases. The company’s research programs are aimed at addressing conditions with significant unmet medical needs, including pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF).

Tenax’s lead product candidate is TNX-103, an oral formulation of levosimendan. Levosimendan is a calcium sensitizer and potassium-channel activator that has been approved for certain heart-failure indications outside the United States.